Hearing loss is a rapidly growing medical challenge. Right now, 1.5 billion around the globe are affected. According to WHO, this figure will rise to 2.5 billion by 2050. For those affected, limitation or loss of communication and social interaction have a strong impact on their health and quality of life. The implications include cognitive impairment, social isolation, mental health issues, and an increased risk of early dementia.² For direct and indirect hearing loss related costs, there is an estimated global expense of USD 980 billion each year.¹

To date, no medications have been approved for the treatment of the various forms of hearing loss that would overcome the technical limitations of hearing aids and cochlear implants. Acousia develops novel compounds (small molecules) to improve and preserve natural hearing in sensorineural hearing loss (SNHL), thereby addressing a clear unmet medical need. SNHL affects over 90 percent of hearing loss patients. The unique dual mode of action of Acousia’s treatment candidates opens the possibility to both enhance hearing and prevent further loss.

Acousia Therapeutics GmbH products

Acousia - Model ACOU085 - Small Molecule Drug for Hearing Loss